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INTRODUCTION
Gastric cancer is a frequent cause of
death worldwide1. It has been linked to
various environmental factors that differ
around the world. In the United States,
risk factors vary from smoking to eating
salty to heavily processed foods, to the H.
pylori bacteria. Gastric carcinomas are
often therapy resistant and due to their
cellular heterogeneity, this makes it
difficult to establish a “one size fits all”
therapeutic approach in patients.
MiRNAs are small non-coding RNAs that
found to be implicated in gene expression
and regulation. One miRNA in particular,
miR-10b, has been found to be highly
oncogenic on metastatic cancers, with its
overexpression linked to proliferation,
migration, and tumor size. Oncogenic
miRNAs operate via targeting tumor
suppressor genes, silencing expression
and permitting abnormal cells to divide
uncontrollably, contributing to the growth
of cancerous tumors. Increased levels of
miR-10b are associated with poorer
overall survival and serve as a
contributing prognostic factor2.
The limited treatment options around
gastric cancer has led Calin’s group to
develop a novel therapeutic binding miR-
10b. This study reports on the effect of
Compound 25, a derivative of the FDA-
approved therapeutic linifanib. This
compound was developed in
collaboration with the Institute for Applied
Cancer Sciences (IACS) at MD Anderson
Cancer Center.
RESULTS
After treating the three cell lines with
Compound 25, we used microscopy to
assess morphological and phenotypic
changes within the SNU-1 and AGS
cells (gastric cancer cell lines).
Fortunately, we were able to see that
there were minimal differences to the
GES-1 cell line (normal epithelial
gastric line) validating that there was
low miR-10b levels in normal cells,
confirming it as a targeted therapeutic.
By evaluating RNA expression using
PCR, we tested miR-10b expression in
both cell lines and patient samples
derived from a collaborator at MD
Anderson Cancer Center,
supplementing our cancer cell line data.
We identified a reduction of miR-10b
after the treatment with Compound 25
specifically in malignant cells,
correlated with the death of malignant
cells but not of normal cells.
CONCLUSION
Oncogenic miR-10b is upregulated in
gastric cancer cell lines and has
limited to undetectable expression in
a normal gastric line. Compound 25
target miR-10b in cancer cell lines
and has the potential for translational
application in a deadly type of
cancer, the gastric cancer.
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METHODS
The learning step: to gain a strong foundation on my project, I reviewed over 50 papers on
miRNAs and miR-10b in PubMed. After my first week in the laboratory, I was able to perform cell
culture and by the second week, I was maintaining several cell lines across three tissue types. I
shadowed senior colleagues on RNA extraction, cDNA preparation, Western blots, and PCR
techniques. I then learned to plate cells, use the microscope, and start new cell lines. By the
sixth week, I did my own PCR to generate data for an ongoing publication. Afterwards, I was
taught to evaluate and analyze the data.
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HYPOTHESIS 
We hypothesize that miR-10b drives
cancer through binding tumor suppressor
genes and that Compound 25 decreases
binding of miR-10b. Therefore, high miR-
10b expression in gastric cancer cells will
be impacted by the compound, leading to
malignant cell death.
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Our experiments began by plating cells into wells and inserting a sequential dosage of
Compound 25 to find our optimal dosage. For best results, the cells were incubated for up to 48
hours. Pictures were taken at 24 and 48 hours at 4x to compare cell density and morphological
differences between the control wells and the wells treated with 5µM of Compound 25. After 48
hours, we performed RNA extraction, cDNA preparation and conducted a miR-10b quantitative
PCR.
Figure 1: Schematic representation of the cell culture procedure using cell lines AGS, SNU-1, and GES-1.
Figure 2: Process of treatment for cells with Compound 25. After treatment we waited 48 hours then began the PCR 
process including RNA extraction and cDNA preparation. 
Figure 3: Pictures of cells at 24 to 48 hours after treatment with Compound 25. Each condition is represented, with 
control versus 5µm to show the differences between the cells after drug treatment at two time points. 
FUTURE DIRECTIONS
More research will be conducted
regarding the specific mechanism of
miR-10b in gastric cancer metastases
and the specific genes that Compound
25 is targeting.
The experimental step: For our study we cultured three different cell lines. GES-1 is the
human gastric epithelial cell line of normal origin. AGS is an adherent stomach cancer tissue
cell derived from a 54-year-old female. SNU-1 is a metastatic suspension stomach cancer
tissue cell from a 44-year-old male. These cells have been cultured, passaged and split every 2-
3 days.
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